1. Introduction {#sec1-genes-11-00350}
===============

Anterior segment dysgenesis (ASD) is a heterogeneous group of eye disorders affecting the cornea, iris, lens, zonule, trabecular meshwork, Schlemm canal, and ciliary body. Primary defects in migration or differentiation of the mesenchymal cells may cause ASD, and in turn impede aqueous humor outflow and elevate intraocular pressure \[[@B1-genes-11-00350]\]. Increased intraocular pressure is a major risk factor for glaucoma \[[@B2-genes-11-00350]\]. About 50% of individuals with ASD develop glaucoma, which often manifests before the age of 40 years \[[@B3-genes-11-00350],[@B4-genes-11-00350]\].

ASD can present with ophthalmic findings only, such as in Peters anomaly and isolated aniridia, or as part of a multisystemic condition, such as Axenfeld--Rieger (AR; MIM 601542, 601090, 601499), Peters plus (MIM 261540), or SHORT (MIM 269880; short stature-hyperextensibility of joints or hernia or both-ocular depression-Rieger anomaly-teething delay) syndromes. Primary congenital glaucoma (PCG) is included in the ASD spectrum due to the presumed abnormal trabecular meshwork and Schlemm canal development \[[@B1-genes-11-00350],[@B2-genes-11-00350]\].

In large families with multiple affected members, ASD is usually inherited as an autosomal dominant trait, though autosomal recessive inheritance has been reported \[[@B1-genes-11-00350]\]. Well-known ASD genes are CYP1B1 (MIM 601771), FOXC1 (MIM 601090), FOXE3 (MIM 601094), PAX6 (MIM 607108), and PITX2 (MIM 601542) \[[@B1-genes-11-00350]\]. Mutations in PAX6, PITX2, and FOXC1 do not always correlate with specific ASD phenotypes. Patients with AR syndrome and PCG may have FOXC1 mutations. PAX6 mutations can occur in both Peters anomaly and aniridia, and CYP1B1 mutations may be the cause of Peters anomaly and PCG. Phenotype or genotype alone is insufficiently precise to classify or diagnose ASD \[[@B2-genes-11-00350]\]. In the present study, we have investigated the genetic origin of isolated or syndromic ASD in the diverse population of South Florida.

2. Materials and Methods {#sec2-genes-11-00350}
========================

2.1. Subjects {#sec2dot1-genes-11-00350}
-------------

We studied 24 (22 simplex and 2 multiplex) unrelated ASD-affected individuals (probands). Affected or unaffected family members were available for the study in 13 families. Families were recruited through the Bascom Palmer Eye Institute at the University of Miami, Miami, Florida. Probands were consecutive patients seen by an ophthalmologist for clinical diagnosis and management of ASD. Clinical evaluation of all affected individuals by an ophthalmologist included a slit lamp examination and dilated fundus exam. Further imaging and laboratory tests were performed when needed. DNA was extracted from peripheral leukocytes of each proband by standard protocols.

2.2. Genetic Screening {#sec2dot2-genes-11-00350}
----------------------

We performed exome sequencing (ES) in the Hussman Institute for Human Genomics at the University of Miami. We used Agilent SureSelect Human All Exon 60 Mb V6 for in-solution enrichment of coding exons and flanking intronic sequences following the manufacturer's standard protocol (Agilent). A HiSeq 3000 instrument (Illumina) was used for sequencing and Genome Analysis Toolkit software package used for variant calling \[[@B5-genes-11-00350],[@B6-genes-11-00350]\]. During the analysis, we focused on specific genes with putative pathogenic variants previously found in individuals with ASD ([Supplementary Materials](#app1-genes-11-00350){ref-type="app"} [Table S1](#app1-genes-11-00350){ref-type="app"}).

We used Enlis genome software (<https://www.enlis.com/>) for annotation and variant filtering. As recommended, we filtered variants based on minor allele frequency of \<0.005 in gnomAD ([www.gnomad.broadinstitute.org](www.gnomad.broadinstitute.org)) when considering a recessive mode of inheritance and \<0.0005 when considering a dominant mode of inheritance \[[@B7-genes-11-00350],[@B8-genes-11-00350]\]. Combined annotation dependent depletion (<http://cadd.gs.washington.edu/>) \[[@B9-genes-11-00350]\], MutationTaster (<http://www.mutationtaster.org/>) \[[@B10-genes-11-00350]\], and sorting intolerant from tolerant (<http://sift.bii.a-star.edu.sg/>) \[[@B11-genes-11-00350]\] in silico analysis tools were used for the pathogenicity prediction. Conservation of the variant was evaluated by using genomic evolutionary rate profiling (<http://mendel.stanford.edu/SidowLab/downloads/gerp/>) \[[@B12-genes-11-00350]\]. We used copy number inference from exome reads to detect copy number variants \[[@B13-genes-11-00350],[@B14-genes-11-00350]\]. Sanger sequencing was performed to confirm the variants, and when other family members were available only those that showed complete segregation with the phenotype in the entire family were considered pathogenic. We used the American College of Medical Genetics guidelines to interpret variant pathogenicity \[[@B15-genes-11-00350],[@B16-genes-11-00350]\].

3. Results {#sec3-genes-11-00350}
==========

Based on the clinical evaluations, seven probands were considered to have syndromes associated with ASD (AR, Peters plus, and oculo--dento--digital syndromes (MIM 164200)), and 17 were diagnosed with isolated eye anomalies ([Supplementary Materials](#app1-genes-11-00350){ref-type="app"} [Table S2](#app1-genes-11-00350){ref-type="app"}). On average, each exome had 99.2%, 95.3%, and 89.4% of mappable bases of the Gencode defined exome represented by coverage of 1×, 5×, and 10× reads for ES, respectively. The average read depth was 71.9× and the coverage and average read depth are considered adequate for exome sequencing \[[@B17-genes-11-00350],[@B18-genes-11-00350]\]. We detected nine pathogenic or likely pathogenic variants and three variants of uncertain significance (VUS) that potentially explain the observed phenotypes in 10 probands out of 24 (42%) ([Figure 1](#genes-11-00350-f001){ref-type="fig"}, [Table 1](#genes-11-00350-t001){ref-type="table"}, [Table 2](#genes-11-00350-t002){ref-type="table"}, [Supplementary Materials Figure S1 and Table S3](#app1-genes-11-00350){ref-type="app"} show phenotypic features of unsolved probands).

4. Discussion {#sec4-genes-11-00350}
=============

In this study, we detected potentially causative variants in 42% of probands with ASD, which is higher than the reported proportion, which ranges from 10% to 25% \[[@B27-genes-11-00350]\]. [Table 3](#genes-11-00350-t003){ref-type="table"} summarizes the characteristics of different genetic studies on ASD. Potential explanations for a higher detection rate of causative variants in our cohort are ethnicities studied, differences in case selection, the number of genes analyzed, and sample size. Our cohort consisted of a unique demographic from South Florida, including large Hispanic and Caribbean populations. Earlier studies focused on European, Asian, African, and Middle Eastern populations \[[@B27-genes-11-00350],[@B28-genes-11-00350]\]. We did not identify recurrent variants enriched in our cohort; the difference between ethnicities of our cohort and those of earlier studies does not appear to explain our higher detection rate. In our cohort, families with Hispanic ancestry appear to have a higher detection rate (Hispanic vs. non-Hispanic is 7/12 vs. 3/12). Additionally, the difference between whites and blacks is noticeable: only 1 out of 7 black families is solved while 9 of 17 white families studied are found to have potentially causative variants. The majority of our black families were from the Caribbean, suggesting that the underlying genetic factors of ASD in the Caribbean remain largely unknown. Another important difference between our study and previous studies is the spectrum of ASD being analyzed. We looked at a wide range of ASD conditions, such as Peters anomaly, aniridia, AR syndrome, and PCG. Some other studies focused on a specific phenotype, such as Peters anomaly \[[@B23-genes-11-00350]\] or primary open-angle glaucoma/primary angle-closure glaucoma \[[@B27-genes-11-00350]\]. Recognized gene variants for some focused phenotypes are present in smaller portions of affected individuals, which likely contributes to higher detection rate in our study. We used ES to cover all genes previously associated with ASD and some previous studies used gene panels, which may not include all associated genes ([Supplementary Materials Tables S1 and S4](#app1-genes-11-00350){ref-type="app"}). While targeted next-generation sequencing gene panels potentially provide higher coverage for individual genes and lower cost, ES as a research tool reduces the need of development and validation of custom panels. Finally, our cohort is smaller in size compared to previous cohorts and may have a higher detection rate by chance.

Identified variants in PAX6, FOXC1, TP63, BMP4, B3GLCT, and GJA1 are considered likely pathogenic or pathogenic based on American College of Medical Genetics (ACMG) guidelines. It should be noted that while GJA1 variant was de novo we did not confirm the parental origin. One proband with Peters anomaly was heterozygous for two VUSs in PXDN. One variant is a change from leucine to proline in position 1274. This variant affects a conserved residue and is predicted to affect protein function with a rare exome ensemble learner (REVEL) score of 0.776, which is a combination of 13 individual tools for pathogenicity prediction of missense variants \[[@B29-genes-11-00350]\]. The second variant shows a change from serine to leucine in position 759. This missense variant is also predicted to make an impact on protein function with a REVEL score of 0.8399. Each parent is heterozygous for one variant suggesting that these two variants are in trans ([Figure 1](#genes-11-00350-f001){ref-type="fig"}). Biallelic PXDN variants have been reported with various eye anomalies including microphthalmia, congenital cataracts, microcornea, sclerocornea, and glaucoma \[[@B30-genes-11-00350],[@B31-genes-11-00350]\]. Therefore, it is possible that the identified variants are the cause of Peters anomaly in our patient. Similarly, one proband was homozygous for the FOXE3 p.I97M variant, which is a VUS. The allele frequency of this variant on gnomAD is 0.00002015. Multiple in silico prediction tools show a damaging effect. This variant has been previously reported in a case with ASD \[[@B26-genes-11-00350]\]. Therefore, we consider the FOXE3 variant a likely cause of the eye phenotype in our proband.

The observed phenotypes in the 10 probands and the variants identified are generally consistent with prior studies. However, in family five, the proband is heterozygous for a TP63 gene variant. Typically, TP63 mutations have been reported in Rapp--Hodgkin (MIM 129400), ADULT (acro--dermato--ungual--lacrimal--tooth; MIM 103285), EEC (ectrodactyly--ectodermal dysplasia--cleft lip/palate; MIM 604292), Hay--Wells (MIM 106260), limb--mammary (MIM 603543), and split hand/foot malformation (MIM 605289) syndromes. In addition to various systemic anomalies, eye findings of these syndromes include blue irides, photophobia, blepharophimosis, blepharitis, dacryocystitis, and lacrimal duct abnormalities \[[@B32-genes-11-00350],[@B33-genes-11-00350],[@B34-genes-11-00350],[@B35-genes-11-00350],[@B36-genes-11-00350],[@B37-genes-11-00350]\]. Our proband was diagnosed with Peters anomaly in the right eye as well as with syndactyly of third and fourth toes in the left foot, vesicoureteral reflux, cleft lip and palate, possible glaucoma, and nasolacrimal abnormalities. All of these findings except for Peters anomaly have been reported in patients with TP63 variants. Another TP63 variant (p.R343W) affecting the same amino acid residue has been reported in a patient with glaucoma and decreased central corneal thickness as well as findings consistent with lacrimo--auriculo--dento--digital syndrome (MIM 149730) \[[@B38-genes-11-00350]\]. Peters anomaly in our patient and decreased corneal thickness associated with glaucoma in the previously reported patient may suggest that the Arg343 residue of TP63 plays a role in corneal development.

Some limitations of our study include the variety of ASD diagnoses among our patient sample. Our study encompasses patients with Peters anomaly, aniridia, AR syndrome, and PCG. Since the sample size is small for each ASD condition, it is difficult to assess the mutation detection rate in each ASD condition. Small family size and incomplete phenotypic evaluation of first-degree relatives made segregation studies difficult. Expected dominant transmission or de novo occurrence in families 3, 5, 6, and 11 could not be demonstrated due to unavailability of parental samples and lack of phenotypic evaluation of parents. Moreover, we did not identify a potentially causative variant in over half of our probands. With the available ES data and an increased cohort in the future, we expect to identify more variants to characterize the genetic features of ASD in South Florida. Finally, variants located in regulatory regions such as introns, promoters, and enhancers, may be studied with genome sequencing in the future.

5. Conclusions {#sec5-genes-11-00350}
==============

We studied 24 families with ASD from South Florida and identified DNA variants potentially explaining 42% of our cohort. Further studies are required to compare different ASD demographics and identify underlying genetic variants on a larger scale.

We are grateful to the participating families and Jill Jensen La Vea for her generous philanthropic support.

The following are available online at <https://www.mdpi.com/2073-4425/11/4/350/s1>, Table S1: List of the genes used for the filtering by using ES in our cohort. Table S2: Syndromic and isolated subjects in both solved and unsolved probands. Table S3: Phenotypic features of the unsolved probands. Table S4: Characteristics of common genes for anterior segment dysgenesis. Figure S1: Representation of the PAX6 gene deletion by using CoNiFER.
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genes-11-00350-t001_Table 1

###### 

Summary of the identified variants in this study.

  Family ID   Gene         Transcript    Inh          Zyg   cDNA                            Amino Acid Change   gnomAD       CADD   GERP RS               MutationTaster                        SIFT   ACMG   ACMG Guidelines                     Reference
  ----------- ------------ ------------- ------------ ----- ------------------------------- ------------------- ------------ ------ --------------------- ------------------------------------- ------ ------ ----------------------------------- --------------------------------------------------
  1           *PAX6*       NM_000280.4   AD           HT    Large deletion (\~266,752 bp)   Large deletion      N/A          N/A    N/A                   N/A                                   N/A    LP     PVS1                                Aradhya, 2012 \[[@B19-genes-11-00350]\]
  3           *FOXC1*      NM_001453.2   AD           HT    c.316C\>T                       p.Q106\*            N/A          38     3.8599                DC                                    N/A    P      PVS1, PM2, PP3, PP5                 Dhaene, 2011 \[[@B20-genes-11-00350]\]
  5           *TP63*       NM_003722.4   AD           HT    c.1028G\>A                      p.R343Q             N/A          33     5.8299                DC                                    DM     LP     PS3, PM2, PM5, PP3                  Ianakiev, 2000 \[[@B21-genes-11-00350]\]
  6           *BMP4*       NM_130851.3   AD           HT    c.521dupG                       p.F175Lfs\*8        N/A          35     5.1999                DC                                    N/A    P      PVS1, PM2, PP3                      This study
  8           *PXDN*       NM_012293.2   AR           HT    c.3821T\>C                      p.L1274P            N/A          25.8   5.4099                DC                                    DM     VUS    PM2, PP3                            This study
  HT          c.2276C\>T   p.S759L       0.00001204   32    5.63                            DC                  DM           VUS    PM2, PP3,             This study                                                                              
  10          *B3GLCT*     NM_194318.3   AR           HT    c.660+1G\>A                     Splice              0.0007602    34     6.0799                DC                                    N/A    P      PVS1, PP3, PP5                      Lesnik Oberstein, 2006 \[[@B22-genes-11-00350]\]
  HT          c.1234C\>T   p.R412\*      N/A          36    3.23                            DC                  N/A          P      PVS1, PM2, PP3, PP5   Weh, 2014 \[[@B23-genes-11-00350]\]                                                     
  11          *FOXC1*      NM_001453.2   AD           HT    c.254dupC                       p.L86Afs\*220       N/A          33     0.5139                DC                                    N/A    P      PVS1, PM1, PM2                      This study
  12          *GJA1*       NM_000165.4   AD           HT    c.119C\>T                       p.A40V              N/A          25.5   6.1599                DC                                    DM     P      PS3, PM1, PM2, PM6, PP2, PP3, PP5   Paznekas, 2003 \[[@B24-genes-11-00350]\]
  14          *CYP1B1*     NM_000104.3   AR           HM    c.535delG                       p.A179Rfs\*18       0.00004797   24.2   2.5599                DC                                    N/A    P      PVS1, PM2, PP5                      Belmouden, 2002 \[[@B25-genes-11-00350]\]
  18          *FOXE3*      NM_012186.2   AR           HM    c.291C\>G                       p.I97M              0.00002015   22.4   1.1799                DC                                    DM     VUS    PM2, PP3                            Quiroz-Casian, 2018 \[[@B26-genes-11-00350]\]

ACMG: American College of Medical Genetics guidelines, AD: autosomal dominant, AR: autosomal recessive, CADD: combined annotation dependent depletion, DC: disease-causing, DM: damaging, GERP RS: genomic evolutionary rate profiling rejected substitution, gnomAD: genome aggregation database, HM: homozygous, HT: heterozygous, Inh: inheritance, LP: likely pathogenic, N/A: not available, P: pathogenic, SIFT: sorting intolerant from tolerant, VUS: variants of uncertain significance, Zyg: zygosity.

genes-11-00350-t002_Table 2

###### 

Phenotypic features of probands with causative variants.

  Family-Individual ID   Sex   Simplex/Multiplex   Age (Years)   Ethnicity             Eye Phenotype                  Additional Clinical Features                                                                                                        Gene
  ---------------------- ----- ------------------- ------------- --------------------- ------------------------------ ----------------------------------------------------------------------------------------------------------------------------------- ----------
  1-II:1                 M     Sx                  9             Black, non-Hispanic   Aniridia with glaucoma         \-                                                                                                                                  *PAX6*
  3-II:1                 M     Sx                  11            White, non-Hispanic   AR with glaucoma               \-                                                                                                                                  *FOXC1*
  5-II:1                 M     Sx                  9             White, Hispanic       Peters anomaly OD              Syndactyly of third and fourth toes in the left foot, vesicoureteral reflux, cleft lip and palate, and nasolacrimal abnormalities   *TP63*
  6-II:1                 F     Sx                  9             White, Hispanic       Peters anomaly OU              \-                                                                                                                                  *BMP4*
  8-II:1                 M     Sx                  8             White, non-Hispanic   Peters anomaly OU              \-                                                                                                                                  *PXDN*
  10-II:1                F     Sx                  8             White, Hispanic       Peters anomaly OU              \-                                                                                                                                  *B3GLCT*
  11-II:1                F     Sx                  37            White, Hispanic       AR with glaucoma               \-                                                                                                                                  *FOXC1*
  12-II:1                M     Sx                  13            White, Hispanic       Microphthalmia with glaucoma   Microdontia, underdeveloped alae nasi, syndactyly                                                                                   *GJA1*
  14-II:1                M     Sx                  13            White, Hispanic       Peters anomaly OU              \-                                                                                                                                  *CYP1B1*
  18-II:1                M     Sx                  6             White, Hispanic       Peters anomaly OU              \-                                                                                                                                  *FOXE3*

AR: Axenfeld--Rieger anomaly, ASD: anterior segment dysgenesis, F: female, M: male, OD: right eye, OS: left eye, OU: both eyes, Sx: simplex.

genes-11-00350-t003_Table 3

###### 

Causative variant detection in published studies.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies                                  Sample Size   Phenotypes                                                     Population Studied                        ES or Gene Panel                                                    Causative Variants Detected in ASD
  ---------------------------------------- ------------- -------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------
  Weh et al. \[[@B23-genes-11-00350]\]     27            Syndromic Peters anomaly: 20\                                  Children's Hospital of Wisconsin (USA)\   ES                                                                  22.2% overall
                                                         Isolated Peters anomaly: 7                                     Population subtypes were not mentioned                                                                        

  Huang et al. \[[@B27-genes-11-00350]\]   257           POAG: 125\                                                     Chinese: 257                              ES of 43 genes associated with ASD, microcornea or microphthalmia   10.9% overall\
                                                         PACG: 132                                                                                                                                                                    POAG: 8.80%\
                                                                                                                                                                                                                                      PACG: 12.9%

  Patel et al. \[[@B28-genes-11-00350]\]   277           MAC: 98 cases\                                                 White European: 139\                      Oculome panel of 429 known eye disease genes                        24.5% overall\
                                                         ASDA: 113 cases\                                               South Asian: 21\                                                                                              Congenital cataracts and lens-associated conditions: 88.9%\
                                                         Other or syndromic: 8 cases\                                   Black African: 7\                                                                                             RET: 42.8%\
                                                         RET: 49 cases\                                                 Arabic or Middle Eastern: 5\                                                                                  Other or syndromic: 37.5%\
                                                         Congenital cataracts and lens-associated conditions: 9 cases   Black Caribbean: 2\                                                                                           ASD: 24.8%
                                                                                                                        Unknown: 91\                                                                                                  
                                                                                                                        Mixed/unclassified: 12                                                                                        

  This study                               24            Peters anomaly: 8\                                             White, Hispanic: 11 (7 solved)\           ES of 92 genes associated with eye phenotypes                       42% overall\
                                                         PCG: 6\                                                        Black, Hispanic: 1 (0 solved)\                                                                                Peters anomaly: 75%\
                                                         AR: 5\                                                         White, non-Hispanic: 6 (2 solved)\                                                                            Aniridia: 50%\
                                                         Aniridia: 2\                                                   Black, non-Hispanic: 6 (1 solved)                                                                             Others: 50%\
                                                         Congenital corneal dystrophy: 1\                                                                                                                                             AR: 40%
                                                         Microphthalmia with glaucoma: 1                                                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASD: anterior segment dysgenesis, ASDA: anterior segment developmental anomalies including glaucoma, ES: exome sequencing, MAC: microphthalmia--anophthalmia--coloboma, PACG: primary angle-closure glaucoma, POAG: primary open-angle glaucoma, RET: retinal dystrophies.
